Home » The MHRA 2026 Regulatory Roadmap Explained

The MHRA 2026 Regulatory Roadmap Explained

Learn how the MHRA 2026 Regulations will impact UKCA compliance, IVD classifications, AI medical devices, IRP pathways, and post-market surveillance.

Updated 21st May 2026

The MHRA 2026 Roadmap: Navigating the New Draft Regulations for Medical Devices & IVDs

The UK medical device regulatory framework is undergoing its biggest transformation since Brexit. The MHRA’s draft Medical Devices (Amendment) Regulations 2026 introduce major changes including the International Reliance Pathway (IRP), stricter IVD classifications, AI and software oversight through PCCPs, and enhanced post-market surveillance obligations. This guide explains what the new regulations mean for manufacturers, UK Responsible Persons, and regulatory teams preparing for the future of UKCA compliance.

The UK Medical Device Regulatory Landscape Has Changed

The UK medical device and IVD regulatory framework is entering its most significant transformation since Brexit. On 11 May 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) released the draft Medical Devices (Amendment) Regulations 2026, introducing sweeping reforms that will reshape how manufacturers access and maintain products on the Great Britain (GB) market.

The proposed legislation introduces the International Reliance Pathway (IRP), formalises Predetermined Change Control Plans (PCCPs) for AI and software devices, strengthens post-market surveillance obligations, and aligns UK In Vitro Diagnostic (IVD) classification rules with globally recognised risk-based frameworks.

For medical device manufacturers, UK Responsible Persons (UKRPs), importers, and regulatory professionals, these changes are not simply administrative updates — they represent a fundamental shift in compliance strategy, technical documentation expectations, and market access planning.

With the MHRA stakeholder impact survey closing on 19 June 2026, businesses now have a limited opportunity to influence the final legislation before implementation.

What Are the MHRA 2026 Medical Device Regulations?

The Medical Devices (Amendment) Regulations 2026 are designed to modernise the UK medical device framework by:

Increasing patient safety
Aligning with international regulatory standards
Supporting innovation in AI and software medical devices
Improving post-market monitoring
Creating faster access pathways for trusted international approvals
Strengthening transparency and traceability requirements

The draft regulations align heavily with:

EU MDR 2017/745
EU IVDR 2017/746
IMDRF guidance documents
Global Medical Device Nomenclature (GMDN) principles
International UDI frameworks

For many organisations, the reforms will require major updates to:

Quality Management Systems (QMS)
Technical Documentation
Clinical Evaluation Reports (CERs)
Performance Evaluation Reports (PERs)
Risk Management Files
Vigilance procedures
Labelling systems
Supplier oversight processes

From Consultation to Law: What the 2026 Amending Regulations Mean for Your Business

The MHRA’s roadmap signals the end of the post-Brexit “transition era.” Instead of temporary recognition measures and legacy pathways, the UK is building a standalone but internationally aligned regulatory framework.

Manufacturers that prepare early will benefit from:

Faster UK market access
Reduced disruption during implementation
Improved Approved Body readiness
Greater global harmonisation
Lower long-term compliance costs

However, organisations relying on legacy MDD/AIMDD/IVDD documentation may face significant remediation work.

The International Reliance Pathway (IRP): A New Route to UK Market Access

What Is the International Reliance Pathway?

The International Reliance Pathway (IRP) is arguably the most transformative feature of the 2026 regulations.

The pathway allows manufacturers with approvals from recognised international regulators to obtain a Certificate of International Reliance for Great Britain market access.

Recognised jurisdictions include:

United States FDA
Health Canada
Australian Therapeutic Goods Administration (TGA)

The MHRA may expand recognised jurisdictions in future phases.

ISO 13485 consulting services

ISO 13485 is the backbone of medical device compliance.

But proper implementation is not just about documentation. It requires:

Process alignment across departments
Integration with risk management (ISO 14971)
Audit-ready structures and evidence

Explore ISO 13485 consulting services

Need support building or fixing your ISO 13485 QMS? Speak with Patient Guard.

Experienced in building and remediating ISO 13485 systems for both start-up’s and established manufacturers preparing for certification.

Why the IRP Matters for Medical Device Manufacturers

The IRP dramatically reduces duplication between regulatory systems.

Manufacturers with:

FDA 510(k) clearance
PMA approvals
De Novo classifications
Health Canada licences
Australian ARTG inclusion

may be able to leverage existing technical evidence rather than undergoing full independent UK conformity assessment procedures.

Strategic Benefits of the IRP

Potential advantages include:

Faster time-to-market in Great Britain
Lower regulatory costs
Reduced technical review duplication
Improved scalability for global manufacturers
Simplified entry for innovative technologies

For multinational manufacturers already maintaining FDA or TGA approvals, this could significantly accelerate UK commercialisation strategies.

Important Limitations of the International Reliance Pathway

The IRP is not automatic recognition.

Manufacturers must still comply with:

UK labelling requirements
UDI obligations
Post-market surveillance obligations
Vigilance reporting requirements
UK Responsible Person (UKRP) requirements
GB registration obligations

The MHRA also reserves the right to request:

Additional clinical evidence
GB-specific risk data
Supplementary performance evidence
Clarification on intended purpose claims

This is especially relevant where devices differ materially from previously approved international versions.

Software as a Medical Device (SaMD) and AI: PCCPs Explained

What Is a Predetermined Change Control Plan (PCCP)?

The 2026 draft regulations formally introduce Predetermined Change Control Plans (PCCPs) for Software as a Medical Device (SaMD) and AI-enabled medical technologies.

A PCCP allows manufacturers to define anticipated software modifications in advance during the initial regulatory submission.

This is particularly important for:

Machine learning systems
Adaptive AI algorithms
Cloud-connected medical software
Cybersecurity patching
Continuous software deployment models

Why PCCPs Are Critical for AI Medical Devices

Historically, even small algorithm updates could trigger:

Re-certification
Additional technical review
Delays in deployment
Increased compliance costs

The PCCP framework supports agile software development while maintaining regulatory oversight.

Manufacturers can pre-authorise:

Performance tuning
Software patches
Cybersecurity improvements
Limited algorithm refinements
User interface improvements

This creates a more realistic compliance model for modern AI-driven healthcare technology.

Software Classification Changes Under the MHRA 2026 Draft

The MHRA is also aligning more closely with IMDRF and EU MDR Rule 11 software classification principles.

Many software products are expected to move into:

Class IIa
Class IIb
Class III

Higher-risk software categories may include:

Diagnostic AI systems
Clinical decision support software
Oncology prediction platforms
Monitoring algorithms
Treatment recommendation systems

This means more software manufacturers will require:

UK Approved Body involvement
Enhanced clinical evidence
Formal PMS systems
Stronger cybersecurity controls

UK IVD Classification Reform: Transition to Classes A–D

The End of the Legacy IVD Framework

The UK is replacing its outdated IVD classification system with the internationally recognised risk-based structure:

Class A
Class B
Class C
Class D

This mirrors the EU IVDR framework and significantly increases scrutiny for higher-risk IVDs.

High-Risk Class D IVD Requirements

Class D IVDs — such as blood screening tests and high-risk infectious disease diagnostics — will face the most rigorous oversight.

Manufacturers will need:

Performance Evaluation Reports (PERs)
Scientific validity evidence
Analytical performance data
Clinical performance evidence
Ongoing lifecycle updates

The MHRA also expects PERs to become “living documents” continuously updated throughout the product lifecycle.

Impact on IVD Manufacturers

Many legacy self-certified IVDs may now require:

Approved Body review
Expanded technical documentation
Post-market performance follow-up
Additional stability studies
Usability validation
Enhanced vigilance systems

This transition could create substantial workload pressures across the IVD industry.

Technical Documentation Requirements Are Becoming Much Stricter

Readily Searchable Technical Documentation

The MHRA is moving away from fragmented legacy technical files toward fully searchable digital documentation systems.

Manufacturers should expect requirements for:

Structured electronic documentation
Clear traceability
Integrated risk management
Version-controlled records
Digital audit trails

This aligns with modern expectations for regulatory inspections and remote assessments.

Expanded Medical Device Data Retention Periods

The draft regulations extend document retention obligations to:

Device lifetime plus 10 years
Device lifetime plus 15 years for implantable devices

This aligns closely with EU MDR requirements.

Manufacturers still operating under older MDD systems may need major updates to:

Record retention policies
Supplier agreements
Archiving procedures
Complaint handling systems

Essential Requirements Are Being Re-Anchored to MDR GSPRs

The MHRA’s Essential Requirements are now heavily aligned with EU MDR General Safety and Performance Requirements (GSPRs).

Key focus areas include:

Chemical and Physical Safety

Manufacturers must strengthen evidence relating to:

CMR substances
Phthalates
Material biocompatibility
Toxicological risk assessment
Chemical exposure justification

Cybersecurity and Connected Devices

The draft regulations place significantly greater emphasis on:

Network security
Data protection
Software resilience
Penetration testing
Vulnerability management
Cybersecurity lifecycle maintenance

This is particularly relevant for:

Connected medical devices
Cloud-based systems
Remote monitoring technologies
Wearable devices
AI-enabled platforms

New Rules for Custom-Made Medical Devices

Increased Oversight for Custom-Made Implantables

The 2026 regulations significantly tighten controls over custom-made devices (CMDs).

Class IIb and Class III custom-made implantable devices will now require:

UK Approved Body QMS certification
Stronger technical documentation
Enhanced traceability
Formal design controls

This marks a major shift away from lighter-touch historical oversight.

Electronic Prescriptions for CMDs

The draft also allows electronic prescriptions for custom-made devices.

Benefits include:

Faster workflows
Improved supply chain efficiency
Better traceability
Stronger digital audit trails
Reduced administrative burden

Implant Cards Become Mandatory

Manufacturers of implantable devices must now provide Implant Cards to patients.

These cards must include:

UDI information
Device name
Serial number
Manufacturer information
Safety warnings
Precautions for patients and healthcare professionals

This improves:

Patient transparency
Traceability
Long-term device monitoring
Incident investigation efficiency

Post-Market Surveillance (PMS) and Vigilance Reporting Changes

Strengthened Vigilance Timelines

The MHRA is reinforcing rapid incident reporting requirements.

New Reporting Deadlines

Serious Public Health Threats → within 2 calendar days
Death or Serious Deterioration → within 10 calendar days
Trend Reporting → mandatory statistical analysis of incident increases

Trend Reporting Requirements

Manufacturers must implement statistical methodologies capable of identifying:

Significant incident increases
Emerging risk patterns
Benefit-risk deterioration
Recurring usability failures
Software anomaly trends

This increases expectations around:

PMS data analytics
Complaint trending
CAPA systems
Signal detection processes

UKCA Marking, CE Mark Recognition, and Transition Timelines

Will CE-Marked Devices Still Be Accepted?

The MHRA consultation on indefinite CE recognition closed in April 2026.

Currently:

CE-marked devices remain accepted under transitional provisions
Recognition extends until 2028 or 2030 depending on device category

However, the 2026 regulations clearly establish the long-term standalone UKCA framework.

Manufacturers should not assume indefinite CE acceptance.

The June 19, 2026 MHRA Stakeholder Deadline

Why the MHRA Impact Survey Matters

The current Call for Evidence provides manufacturers with a critical opportunity to influence the final regulations before formal implementation.

The MHRA is specifically requesting industry feedback regarding:

UDI implementation costs
Economic impact of PER requirements
IRP administrative burden
Cybersecurity compliance costs
PMS implementation challenges

Key Deadline

Stakeholder responses must be submitted by:

19 June 2026

Manufacturers that fail to engage may lose an important opportunity to shape practical implementation.

Frequently Asked Questions About the MHRA 2026 Regulations

Does the MHRA Accept CE-Marked Devices Indefinitely?

No. Transitional recognition remains in place temporarily, but the UK is moving toward a standalone UKCA-based framework.

Can Legacy Clinical Data Be Used for IRP Submissions?

Potentially yes — but only where the device remains comparable in:

Design
Intended purpose
Materials
Clinical performance
Safety profile

The MHRA may request supplementary UK-specific evidence where clinically significant differences exist.

What Is Regulation 19D?

Regulation 19D introduces prohibitions against misleading or unsubstantiated promotional claims.

This creates stronger legal enforcement powers against:

False safety claims
Unsupported performance statements
Misleading intended purpose claims
Non-compliant marketing materials

How Manufacturers Should Prepare for the MHRA 2026 Changes

Medical device and IVD manufacturers should begin preparations immediately.

Recommended actions include:

Conduct a Full Regulatory Gap Analysis

Review:

What is included in ISO 27001 implementation?

Information security frameworks, risk assessments, and cybersecurity controls aligned with regulatory expectations.

How do I prepare for a regulatory audit?

Ensure your systems, documentation, and processes are aligned, current, and consistently implemented.

Review Software Classification Rules

Assess whether your software products may be up-classified under the new framework.

Prepare for Enhanced IVD Requirements

IVD manufacturers should begin:

PER development
Performance evidence review
Classification mapping
PMS strengthening

Strengthen Post-Market Surveillance Systems

Ensure your PMS framework supports:

Trend reporting
Statistical analysis
Vigilance timelines
Signal detection

Engage with the MHRA Consultation

The June 2026 survey is one of the last opportunities to influence implementation details.

Why Early Preparation Is Essential

Approved Body and regulatory capacity constraints remain a global challenge.

Manufacturers delaying preparation risk:

Market access delays
Certification bottlenecks
Increased remediation costs
Product registration interruptions
Supply chain disruption

Early action will be critical for uninterrupted access to the UK market.

Need Help Navigating the MHRA 2026 Regulations?

At Patient Guard Ltd, we help medical device and IVD manufacturers translate complex regulations into practical compliance strategies.

Our regulatory specialists support:

UK Responsible Person (UKRP) services
UKCA compliance
IVD Performance Evaluation Reports
Clinical Evaluation Reports
PMS and Vigilance systems
Technical Documentation remediation
Gap Analyses
AI and software device compliance
MDR/IVDR transition projects

Whether you need strategic guidance or full regulatory implementation support, our team is ready to help.

Contact Patient Guard Ltd to discuss your UK medical device compliance strategy before the new regulations take effect.

Alex Lewis, BSc, Qualified Lead Auditor

Reviewed by
Alex Lewis, BSc
Quality Assurance Manager | ISO 13485 Lead Auditor
15+ years in medical device regulatory affairs, ISO 27001, ISO 9001, MDR/IVDR compliance and quality systems.

Patient Guards Recent Posts